BG
AKCA

Bellevue Group’s Akcea Therapeutics Inc AKCA Stock Holding History

Bellevue Group’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-340,264
Closed -$6.17M – 234
2020
Q3 		$6.17M Sell
340,264
-1,122,032
-77% -$15.9M 0.09% 122
2020
Q2 		$20M Sell
1,462,296
-1,741,948
-54% -$26.9M 0.28% 79
2020
Q1 		$45.8M Buy
3,204,244
+41,601
+1% +$683K 0.89% 32
2019
Q4 		$53.6M Buy
3,162,643
+52,732
+2% +$981K 0.85% 36
2019
Q3 		$47.9M Buy
3,109,911
+9,143
+0.3% +$195K 0.89% 32
2019
Q2 		$72.7M Buy
3,100,768
+2,596,357
+515% +$64.1M 1.24% 25
2019
Q1 		$14.3M Buy
504,411
+46,115
+10% +$1.34M 0.79% 43
2018
Q4 		$13.8M Buy
458,296
+39,800
+10% +$1.12M 0.91% 33
2018
Q3 		$14.7M Buy
418,496
+39,195
+10% +$1.19M 0.93% 38
2018
Q2 		$8.99M Buy
379,301
+330,502
+677% +$7.89M 0.77% 46
2018
Q1 		$1.25M Buy
+48,799
New +$1.05M 0.12% 102

Bellevue Group's AKCA Position: Q4 2020 in Review

Bellevue Group sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 340,264 shares — an estimated $6.17M sold.

Bellevue Group first reported a position in AKCA in Q1 2018 and held it in 11 quarters. The position peaked at $72.7M in Q2 2019. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • Bellevue Group reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • Bellevue Group sold 340,264 Akcea Therapeutics Inc shares in Q4 2020, an estimated $6.17M.
  • Bellevue Group first reported a position in Akcea Therapeutics Inc in Q1 2018 and held it in 11 quarters.
  • Bellevue Group's Akcea Therapeutics Inc position peaked at $72.7M in Q2 2019.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Bellevue Group's 13F filing for Q4 2020, filed 16 Feb 2021.